Filter Results:
(924)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Show Results For
- All HBS Web
(1,279)
- People (5)
- News (171)
- Research (924)
- Events (6)
- Multimedia (12)
- Faculty Publications (757)
Sort by
- 05 Jul 2006
- Working Paper Summaries
Do Managers’ Heuristics Affect R&D Performance Volatility? A Simulation Informed by the Pharmaceutical Industry
- February 1990
- Background Note
Note on Pharmaceutical Marketing Practices in the Third World (Edited)
Smith, N. Craig, and John A. Quelch. "Note on Pharmaceutical Marketing Practices in the Third World (Edited)." Harvard Business School Background Note 590-032, February 1990.
- 2012
- Report
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
By: Mark R. Kramer, Kyle Peterson, Matthew Rehrig, Mike Stamp and Samuel Kim
Examples of how pharmaceutical and medical companies are addressing unmet health needs in low- and middle- income economies, creating shared value by providing products and services that tackle global health problems. View Details
Keywords: Shared Value; Low- And Middle-income Economies; Health Care and Treatment; Global Range; Pharmaceutical Industry; Pharmaceutical Industry
Kramer, Mark R., Kyle Peterson, Matthew Rehrig, Mike Stamp, and Samuel Kim. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Report, FSG, 2012.
- September 2017
- Teaching Note
Dr. William Carson— Intrapreneurial Innovation in the Pharmaceutical Industry
By: Steven Rogers and Alyssa Haywoode
Teaching Note for HBS No. 318-005. View Details
- June 1989 (Revised July 1990)
- Background Note
Note on Pharmaceutical Marketing Practices in the Third World
Smith, N. Craig, and John A. Quelch. "Note on Pharmaceutical Marketing Practices in the Third World." Harvard Business School Background Note 589-039, June 1989. (Revised July 1990.)
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- Article
Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research
By: Jeffrey Furman, Margaret K. Kyle, Iain Cockburn and Rebecca M. Henderson
Furman, Jeffrey, Margaret K. Kyle, Iain Cockburn, and Rebecca M. Henderson. "Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research." Annales d'économie et de statistique, nos. 79-80 (July–December 2005).
- May 2024
- Article
Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms
By: Caroline Marra and Ariel D. Stern
Digital health technologies (DHTs) can enable more patient-centric therapeutic development by generating evidence that captures how patients feel and function, enabling decentralized trial designs that increase participant inclusivity and convenience, and collecting... View Details
Keywords: Health Care and Treatment; Technological Innovation; Product Development; Health Testing and Trials; Governing Rules, Regulations, and Reforms
Marra, Caroline, and Ariel D. Stern. "Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms." Clinical Pharmacology & Therapeutics 115, no. 5 (May 2024): 988–992.
- 2001
- Working Paper
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
- July 2002
- Article
Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery
By: Stefan Thomke and Walter Kuemmerle
Thomke, Stefan, and Walter Kuemmerle. "Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery." Strategic Management Journal 23, no. 7 (July 2002): 619–635.
- March 2024
- Article
Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act
By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are... View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- Article
Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry]
By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
mRNA technology has just helped to develop vaccines against COVID-19. Now, like Apple's iOS, it could provide the basis for new innovation platforms. View Details
Keywords: mRNA; COVID-19; Vaccines; Health Care and Treatment; Health Pandemics; Innovation and Invention; Health Industry
Stern, Ariel Dora, Timo Minssen, W. Nicholson Price, II, and Christoph Grimpe. "Ein Booster für die Pharmabranche [A Booster for the Pharmaceutical Industry]." Harvard Business Manager (July 2022).
- 2014
- Working Paper
The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories
By: Francesca Lazzeri and Gary P. Pisano
Scholars and practitioners alike now recognize that a firm's capacity to assimilate and use know-how from external sources—what Cohen and Levinthal (1990) called "absorptive capacity"—plays a central role in innovation performance. In recent years, a common strategy... View Details
Keywords: Geographic Location; Industry Clusters; Knowledge Acquisition; Pharmaceutical Industry; San Francisco; San Diego; Massachusetts
Lazzeri, Francesca, and Gary P. Pisano. "The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories." Harvard Business School Working Paper, No. 14-098, April 2014.
- February 2016 (Revised February 2017)
- Case
Alvogen
By: Daniel Isenberg and William Kerr
Alvogen is a young Icelandic generic pharmaceutical company, whose CEO believes that his global strategy will give them an edge in this competitive industry.
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Keywords: Pharmaceutical Companies; Generic Drugs; Entrepreneurship; Globalization; Risk and Uncertainty; Pharmaceutical Industry; Iceland
Isenberg, Daniel, and William Kerr. "Alvogen." Harvard Business School Case 816-064, February 2016. (Revised February 2017.)
- March 2013
- Teaching Note
Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)
By: David J. Collis
- July 2019
- Article
The Impact of Price Regulation on the Availability of New Drugs in Germany
By: Ariel Dora Stern, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim and Ameet Sarpatwari
The 2011 German Pharmaceutical Market Restructuring Act (“AMNOG”) subjected branded, non-rare disease drugs to price regulation based on an assessment of their clinical benefit. Assessment outcomes range from “major added benefit” to “less benefit than the appropriate... View Details
Keywords: Regulation; Pharmaceuticals; Healthcare; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Germany
Stern, Ariel Dora, Felicitas Pietrulla, Annika Herr, Aaron S. Kesselheim, and Ameet Sarpatwari. "The Impact of Price Regulation on the Availability of New Drugs in Germany." Health Affairs 38, no. 7 (July 2019): 1182–1187.
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca M. Henderson and Iain Cockburn
Henderson, Rebecca M., and Iain Cockburn. "Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research." Journal of Health Economics 20, no. 6 (November 2001): 32–59.